Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

Sven Wehrwein, a subordinate of the Board of Directors astatine AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified banal options and instantly sold the underlying shares successful derivative transactions connected November 24 and November 25, 2025, arsenic reported successful the SEC Form 4 filing.

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($37.66); post-transaction worth based connected November 25, 2025 marketplace adjacent ($37.66).

• What was the operation and discourse of this insider transaction?
  The transaction progressive the workout of 10,000 non-qualified banal options by Sven Wehrwein, instantly followed by an open-market merchantability of each underlying shares. Following the transaction, nonstop holdings basal astatine 34,374 shares.

• How important was the merchantability comparative to the insider’s anterior activity?
  Since August 2025, Mr. Wehrwein has made 3 administrative sales, cumulatively reducing nonstop holdings by 20,000 shares (36.78% of the starting presumption for the period). The existent 10,000-share merchantability is the largest azygous lawsuit successful this sequence, representing 22.54% of pre-sale nonstop holdings astatine the time.

• How does the transaction terms comparison to caller marketplace levels?
  The transaction terms was $37.66 per share, compared to a existent terms of $36.12 arsenic of November 28, 2025. As of November 28, 2025, shares are priced astatine $36.12, astir 4.1% beneath the transaction price.

• What is the broader institution and marketplace discourse for this trade?
  As of the commercialized date, AtriCure posted a one-year full instrumentality of -0.11%, with a trailing-twelve-month nett nonaccomplishment of $28.8 cardinal connected gross of $518.3 million. Mr. Wehrwein’s nonstop ownership post-sale represents 0.07% of outstanding shares.

Note: 1-year show calculated utilizing November 25th, 2025 arsenic the notation date.

• AtriCure develops and markets devices for surgical ablation of cardiac tissue, including vigor frequence clamps, multifunctional pens, cryoablation systems, and implantable closure devices.

• It generates gross done the merchantability of single-use and reusable aesculapian devices and systems, chiefly targeting the attraction of atrial fibrillation and related cardiac conditions.

• The institution serves hospitals, aesculapian centers, and cardiac surgeons successful the United States and planetary markets via nonstop income and autarkic distributors.